Treasury puts £165m into AI biosecurity and £60m into health AI procurement ahead of the Budget

HM Treasury set out a package of AI spending on 24 October 2026 that the Chancellor will take into next week's Budget, with three strands aimed at health: a £165m National AI Biosecurity Initiative, an extra £60m for a Sovereign AI procurement scheme covering health and care challenges, and a £15m AI Challenge Prize whose first award goes to firms tackling health problems¹. The trade body techUK put the whole package at more than £600m¹.

What the package contains

The biosecurity initiative splits into £100m for a new AI Biosecurity Lab (AIBL), which will use AI to detect and track biological threats, and £65m for biosurveillance and medical countermeasures against priority pathogens¹. The Cabinet Office describes AIBL as the first organisation anywhere dedicated to AI biosecurity and puts total backing at up to £300m once company commitments are counted². Those commitments are:

• OpenAI: £100m in compute and model credits, plus trusted access to its most capable relevant models through its Rosalind Biodefense programme².
• Anthropic: up to £100m in model credits, trusted model access and dedicated technical support².
• Google DeepMind and London-based Basecamp Research: research partnerships and access to AI science tools and AI-biology models¹².

AIBL will run as an independent non-profit modelled on the AI Security Institute, with a scientific advisory committee still to be named². Its first work will focus on earlier detection of emerging biological threats and faster development of vaccines, treatments and other countermeasures². It sits in a national initiative alongside the UK Health Security Agency, the Animal and Plant Health Agency and Dstl, and will work with the MHRA on health emergency preparedness and on how AI-designed medicines are regulated².

Away from biosecurity, the extra £60m for the Sovereign AI R&D Procurement Scheme is meant to buy solutions to problems across health and care as well as in AI security and assurance¹. The Treasury also cited existing NHS results: AI now helps clinicians read more than 210,000 chest X-rays a month, around a third of the NHS total, which it links to an 11.5% rise in suspected lung cancers flagged within 24 hours, about 400 more patients a month, and a fall in the average wait for follow-up CT from 6.3 to 5.6 days¹.

What it means for the market

For AI suppliers to the NHS and to public health, the two procurement lines are the most direct opening: a £60m R&D purchasing scheme with health and care named as a target, and a £15m prize whose first round is reserved for health¹. The scheme's scope is shared with AI security and assurance, so the health share is not specified¹.

For frontier model developers, the lab sets a template in which commercial providers fund national capability largely in kind, through credits and model access rather than cash². The government says it wants AIBL to draw philanthropic as well as public money over time². For drug and vaccine developers, the planned work with the MHRA on regulating AI-designed medicines is the point to watch, though no timetable is given².

"AIBL is a bold investment in UK resilience," said Gordon Sanghera, founder of Oxford Nanopore Technologies¹.

Caveats

These are announcements ahead of the Budget, not allocations with delivery dates; the release gives no timetable for spending the procurement or prize money and no split of the £65m¹. The chest X-ray figures describe existing deployments rather than new funding¹. The membership of AIBL's scientific advisory committee is to be set out later².